Association between hematuria remission at 6 months and subsequent kidney outcomes in IgA nephropathy
Journal of Nephrology · 12.08.2026
DOI: 10.1093/joneph/aajag223 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nephrology, online erschienen am 12.08.2026. Verfasst von Keiko Onoue und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Hiroshima University Hospital, Hiroshima, Japan.
Abstract (Originalsprache)
Background
While proteinuria is a well-established surrogate marker in IgA nephropathy (IgAN), the independent prognostic value of early hematuria remission remains unclear. We hypothesized that treatment response at 6 months, particularly hematuria status, is associated with subsequent kidney outcomes.
Methods
We conducted a single-center retrospective cohort study of biopsy-proven IgAN at Hiroshima University Hospital between April 2010 and March 2024. A 6-month landmark analysis was used to minimize immortal time bias, including patients who were event-free at 6 months, with follow-up starting at that time. Urinary red blood cell (uRBC) count at 6 months was used to classify patients into remission (<5 RBC/high-power field [HPF]), persistent moderate (5–29 RBC/HPF), and persistent severe (≥30 RBC/HPF). The primary outcome was a composite of end-stage kidney disease or a ≥30% decline in the estimated glomerular filtration rate. Multivariable Cox models, Kaplan–Meier analyses, and restricted cubic spline models were performed.
Results
A total of 286 patients were analyzed (median age 43 years; 48.2% male). During a median follow-up of 3.1 years, 38 patients (13.3%) reached the composite outcome. Compared with remission, persistent severe hematuria was associated with higher risk of the outcome (hazard ratio 2.97, 95% confidence interval 1.33–6.67, P = 0.01). Restricted cubic spline analyses demonstrated a graded association between higher uRBC count and worse kidney outcomes.
Conclusion
Persistent severe hematuria at 6 months was independently associated with worse kidney outcomes. Monitoring hematuria at 6 months may provide a clinically useful marker for risk stratification in patients with IgAN.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology, Hiroshima University Hospital, Hiroshima, Japan.
ORCID-Profile: Aiko Okubo, Yujiro Maeoka
Zitieren
APA
Onoue, K., Okubo, A., Yoshida, M., Takahashi, A., Osaki, Y., Ishiuchi, N., Maeoka, Y., Sasaki, K., & Masaki, T. (2026). Association between hematuria remission at 6 months and subsequent kidney outcomes in IgA nephropathy. Journal of Nephrology. https://doi.org/10.1093/joneph/aajag223
Vancouver
Onoue K, Okubo A, Yoshida M, Takahashi A, Osaki Y, Ishiuchi N, et al. Association between hematuria remission at 6 months and subsequent kidney outcomes in IgA nephropathy. Journal of Nephrology. 2026. doi:10.1093/joneph/aajag223
BibTeX
@article{Onoue2026,
author = {Onoue, Keiko and Okubo, Aiko and Yoshida, Maria and Takahashi, Akira and Osaki, Yosuke and Ishiuchi, Naoki and Maeoka, Yujiro and Sasaki, Kensuke and Masaki, Takao},
title = {Association between hematuria remission at 6 months and subsequent kidney outcomes in IgA nephropathy},
journal = {Journal of Nephrology},
year = {2026},
doi = {10.1093/joneph/aajag223}
}
EUVIMED